Lilly's Retatrutide More Than Doubles Ozempic Weight Loss
By @sharedot · · 7 pages
- Health
- Diabetes
- Obesity
- Pharma
- Eli Lilly
Eli Lilly says its triple-G drug retatrutide cut A1C further and delivered over twice Ozempic's weight loss in a head-to-head Phase 3 diabetes trial.
What happened: Lilly unveils head-to-head win over Ozempic
Eli Lilly announced on October 28, 2026 that its investigational once-weekly drug retatrutide beat Novo Nordisk's Ozempic 2 mg — the highest approved dose — in TRANSCEND-T2D-2, a Phase 3 head-to-head trial in 1,298 adults with type 2 diabetes inadequately controlled on metformin.
At 80 weeks, retatrutide met the primary endpoint and all key secondary endpoints. Participants lost an average of 44.3 lbs (19.5%) on the 9 mg dose and 47.4 lbs (20.9%) on the 12 mg dose, compared with 20.9 lbs (9.4%) for Ozempic — more than double the weight loss.
Both retatrutide doses lowered A1C by an average of 2.2% versus 1.8% for Ozempic.
Why it is surprising: a direct comparative upset
Ozempic has become the reference point for diabetes and obesity treatment, so Lilly's choice to measure directly against its rival's top dose — and win on both blood sugar and weight — challenges the current treatment hierarchy.
Lilly executive Kenneth Custer said the results suggest retatrutide, if approved, could shift the treatment paradigm for type 2 diabetes, obesity and related cardiometabolic conditions, especially since weight loss has historically been harder to achieve in people living with type 2 diabetes.
The evidence: numbers beyond the scale
The trial randomized participants 2:2:1 to retatrutide 9 mg, retatrutide 12 mg or Ozempic 2 mg, with a baseline A1C averaging 8.3% and baseline weight of 102.4 kg.
Retatrutide also delivered greater improvements across certain cardiovascular risk factors, including non-HDL cholesterol, triglycerides and systolic blood pressure.
Most common adverse events were gastrointestinal: diarrhea (28.3% on 9 mg, 32.7% on 12 mg vs 26.4%), nausea, constipation, vomiting and dyspepsia, mostly mild-to-moderate and typically resolving during treatment.
Treatment discontinuation due to adverse events was 4.8% on 9 mg, 7.9% on 12 mg and 2.7% on Ozempic.
The stakes: a new contender in a booming market
STAT's national biotech reporter Elaine Chen notes the result lands amid a boom in new obesity treatments, and Lilly markets both Mounjaro (tirzepatide) and Foundayo (orforglipron).
TRANSCEND-T2D-2 is the sixth Phase 3 trial in which retatrutide has shown powerful efficacy, reinforcing its potential to transform cardiometabolic care, according to Lilly.
The molecule is a single agent activating receptors for GIP, GLP-1 and glucagon — a 'triple-G' approach — and is also being studied in obesity, knee osteoarthritis pain, sleep apnea, chronic low back pain, cardiovascular outcomes and metabolic liver disease.
What comes next: approval, comparisons and caution
Detailed results will be presented at a future medical meeting and published in a peer-reviewed journal, per Lilly.
The company is also running TRIUMPH-5, an ongoing Phase 3 head-to-head trial of retatrutide versus its own tirzepatide in adults with obesity with or without type 2 diabetes, and TRANSCEND-T2D-2 includes a 24-week extension for roughly 650 participants to assess long-term efficacy and safety.
Importantly, retatrutide remains investigational: Lilly stresses it has not been approved by the FDA or any regulator anywhere in the world and cannot legally be sold to patients.
Sources
- investor.lilly.com › Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial
- tradingview.com › Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trial
- statnews.com › Lilly's triple-G drug beats Ozempic in head-to-head study